Keywords:
Cancer, Diagnostic procedure, Contrast agent-intravenous, MR, Contrast agents, Breast
Authors:
M. Hansen, S. Bäckström, L. Egeblad, A. Olsson, T. Sivik Sonne, O. Axelsson; Lund/SE
DOI:
10.26044/ecr2019/C-2061
Conclusion
SN132D showed improved CNRs in the 4T1 cancer model with an extended time window for up to 2 - 4 hours after administration.
Toxicology and safety studies of SN132D in rat and minipig showed a favourable safety profile and NOAEL could be identified in both species.
Observed preclinical toxicity at high doses is considered related to Mn.
In-vitro cytotoxicity in all cell lines investigated were due to Mn-induced apoptosis.
The SN132D nanoparticle does not bind irreversibly to plasma proteins,
induce complement activation in vitro in human plasma or serum,
or cause hemolysis of whole blood.
Based on preclinical efficacy and safety,
SN132D holds potential as a novel tumor-selective and gadolinium-free contrast agent for MRI.
A clinical study in breast cancer patients is in preparation.